StocksMedium•20 November 2026•
4 min read

Erasca Reports Confirmed 69% Response Rate for Its Drug in Pancreatic Cancer Patients

By

Key Facts

1The confirmed response rate was 44% among 25 patients with KRAS G12X-mutated pancreatic ductal adenocarcinoma at a dose of 32 mg daily.
2The G12D or G12V group recorded a confirmed response rate of 69% among 13 patients.
3The confirmed response rate was 63% among 8 patients with a G12D mutation and 80% among 5 patients with a G12V mutation.
4Erasca expects to start its Phase 3 pancreatic cancer trial in the first half of 2027.
5At a dose of 32 mg, adverse events led to temporary dose interruption in 13.0% and dose reduction in 16.7% of patients.

Erasca said its investigational drug ERAS-0015 recorded a confirmed objective response rate of 44% among 25 patients with KRAS G12X-mutated pancreatic ductal adenocarcinoma who received treatment in the second line or later, at a dose of 32 mg once daily. The company said the rate reached 69% in a group of 13 patients with KRAS G12D or G12V mutations, which together account for about 70% of pancreatic cancer patients. The results come from the Phase 1 AURORAS-1 trial and are interim data, not results from a pivotal trial or evidence of treatment approval. In the G12X group, 84% had received treatment in the third line or later, while 44% had a G12R mutation. The announcement updates the drug's results and development plans: Erasca said it had accelerated the start of its Phase 3 pancreatic cancer trial to the first half of 2027.

In a mutation analysis within the pancreatic cancer group, the confirmed response rate was 63% among the eight patients with a G12D mutation, compared with 80% among the five patients with a G12V mutation. These subgroup rates are based on a small group, and patient numbers differ between the overall analysis and the mutation-specific analysis. The broader G12X group included 25 patients, with a response rate of 44% at a dose of 32 mg daily. The company said all 11 patients who achieved confirmed responses remained on treatment, as did 6 of 11 patients whose disease was stable. These figures offer an indication that some participants continued treatment, alongside the reported response rates.

The company also reported results in KRAS G12X-mutated non-small cell lung cancer after patients had received an immune checkpoint inhibitor and platinum-based chemotherapy. The confirmed response rate was 60% among 5 patients who received a dose of 32 mg once daily, while a group of 12 patients treated at doses ranging from 16 to 32 mg had a response rate of 58%. The data concern patients in the second or third line after the specified immunotherapy and chemotherapy. Erasca said it expects to start a potential registration-supporting trial in second-line or later RAS-mutated lung cancer during the first half of 2027. It also expects to start a Phase 3 trial in first-line RAS-mutated lung cancer between the second half of 2027 and the first half of 2028.

On safety, Erasca said most treatment-related adverse events were low grade and that no dose-limiting toxicities had been recorded. At a dose of 32 mg, adverse events led to temporary dose interruption in 13.0% of 54 patients and dose reduction in 16.7%, and did not lead to permanent treatment discontinuation in any of them. But the disclosure reports one death related to pneumonitis in a patient with metastatic pancreatic cancer who received a dose of 24 mg; the pneumonitis progressed from grade 3 to grade 5. The company reported the case in April 2026 and said there had been no additional treatment-related grade 5 deaths. The case keeps safety an important part of trial monitoring, alongside the efficacy results reported by the company.

The interim data are from the AURORAS-1 trial, with a data cutoff date of September 1, 2026, according to an Erasca filing with the U.S. Securities and Exchange Commission. The company said some responses were confirmed after the data cutoff date. In KRAS G12X-mutated cholangiocarcinoma, the 32 mg dose produced a confirmed response rate of 75% among four patients, and all three patients with confirmed responses remained on treatment. The company also reported preliminary data for combinations of the drug with other treatments: the gemcitabine and nab-paclitaxel combination passed the dose-limiting toxicity assessment window through a dose of 16 mg with no cases, while the 24 mg dose-escalation cohort was under study and no efficacy data were yet available. For the panitumumab combination, it reported two ongoing confirmed partial responses in two patients who received 24 mg and then had their dose reduced to 16 mg, and one unconfirmed partial response among a group of four who received 16 mg.

Sources

Open on chart